Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma ...

NEW YORK, NY, USA I April 28, 2025 I IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell ...

CAMBRIDGE, MA and ROCKVILLE, MD, USA I April 28, 2025 I Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology with ...

Lead development candidate, AMP-410, leverages proprietary Ampersand technology to block VEGF and allosterically activate 4-1BB signaling – unlike traditional ...

Novel glycan-directed ADC shows preclinical activity in gastric cancer and potential to address underserved patient population ...

VYJUVEK was approved by the FDA in the United States in May 2023 and is also under review for approval by Japan’s Pharmaceuticals and Medical Devices Agency with a decision expected in 2H 2025.

EpiTAC platform can also combine with drug payload delivery to deepen anti-tumor activity and reach broader tumor indications, supporting first-in-class ...

DARMSTADT, Germany I April 28, 2025 I Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.

CAMBRIDGE, MA, USA I April 27, 2025 I Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), ...